The economic cost of epilepsy: a review

被引:11
作者
Brunetti, M [1 ]
Pagano, E [1 ]
Garattini, L [1 ]
机构
[1] Angelo & Angela Vanetti Ctr Hlth Econ, I-24020 Ranica, BG, Italy
来源
ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES | 1998年 / 19卷 / 02期
关键词
epilepsy; costs;
D O I
10.1007/BF02427569
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Epilepsy is the most prevalent chronic neurologic condition. in developed countries, its incidence is 30-50 per 100 000 population per year and the prevalence is approximately 5-8 cases per 1 000 population. The rapid growth of health care expenditures has led to increased interest in economic evaluation of health care programs. We reviewed studies on the costs of epilepsy to assess the significance of their quantitative results, through a specific scheme of analysis. The main findings of our study are that a general consensus on cost of illness evaluation is still remote and many studies lack technical details, making difficult any useful comparison of results. New efforts should be realized to achieve a major degree of standardization in methodological processes.
引用
收藏
页码:116 / 119
页数:4
相关论文
共 26 条
[1]   COST OF ILLNESS STUDIES IN HEALTH-CARE - A COMPARISON OF 2 CASES [J].
AMENT, A ;
EVERS, S .
HEALTH POLICY, 1993, 26 (01) :29-42
[2]  
Australia Commonwealth Department of Human Services and Health, 1995, GUID PHARM IND PREP
[3]  
BANKS GK, 1995, COST EPILEPSY, P39
[4]   COST OF EPILEPSY IN THE UNITED-STATES - A MODEL-BASED ON INCIDENCE AND PROGNOSIS [J].
BEGLEY, CE ;
ANNEGERS, JF ;
LAIRSON, DR ;
REYNOLDS, TF ;
HAUSER, WA .
EPILEPSIA, 1994, 35 (06) :1230-1243
[5]  
BERAN RG, 1995, COST EPILEPSY, P49
[6]   Economic evaluation in healthcare - A brief history and future directions [J].
Blumenschein, K ;
Johannesson, M .
PHARMACOECONOMICS, 1996, 10 (02) :114-122
[7]   THE COST OF EPILEPSY IN THE UNITED-KINGDOM - AN ESTIMATION BASED ON THE RESULTS OF 2 POPULATION-BASED STUDIES [J].
COCKERELL, OC ;
HART, YM ;
SANDER, JWAS ;
SHORVON, SD .
EPILEPSY RESEARCH, 1994, 18 (03) :249-260
[8]  
Davey P J, 1992, Pharmacoeconomics, V2, P5, DOI 10.2165/00019053-199202010-00002
[9]  
DILISO G, 1996, B LEGA IT EPIL, V95, P23
[10]  
Drummond M, 1992, Pharmacoeconomics, V2, P1, DOI 10.2165/00019053-199202010-00001